FT596 Selected by ASH for Feature at CAR-T and Beyond Press Conference on December 7
Two Oral and Four Poster Presentations Covering iPSC-derived Cell-based Cancer Immunotherapy Pipeline Accepted for Presentation
Company to Host Investor Event at ASH on December 6
SAN DIEGO, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that two oral and four poster presentations covering the Companys off-the-shelf, induced pluripotent stem cell (iPSC)-derived natural killer (NK) cell and chimeric antigen receptor (CAR) T-cell product candidates will be featured at the 61st American Society of Hematology (ASH) Annual Meeting and Exposition. The meeting will be held December 7-10, 2019 in Orlando, Florida.
In addition, this years ASH press program will feature the Companys FT596 product candidate. The "CAR-T and Beyond" press briefing will take place at 7:30 a.m. EST, Saturday, December 7, in the ASH Press Briefing Room (W221DE) of the Orange County Convention Center. It is open to all media registered to attend the meeting.
We are honored that FT596 has been selected by the ASH Program Committee for feature in this years prestigious Annual Meeting Press Program, said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics. The multi-antigen targeting functionality and off-the-shelf availability of FT596, combined with the intrinsic anti-tumor activity of NK cells, is a promising approach to overcome antigen escape and time-to-patient treatment, and has the potential to convey deeper and more durable responses to more patients. We look forward to highlighting the breadth of our novel off-the-shelf, iPSC-derived cell-based cancer immunotherapy pipeline this year at ASH.
FT596 is among the first cell-based cancer immunotherapies to be manufactured from a master iPSC line, and is the first-ever cellular immunotherapy allowed for clinical investigation that is genetically engineered to contain three active anti-tumor modalities: a proprietary chimeric antigen receptor (CAR) targeting B-cell antigen CD19; a novel high-affinity, non-cleavable CD16 Fc receptor for enhanced binding to tumor-targeting antibodies; and an interleukin-15 receptor fusion (IL-15RF) for improved potency.
2019 ASH Oral Presentations
2019 ASH Poster Presentations
About Fate Therapeutics iPSC Product Platform
The Companys proprietary induced pluripotent stem cell (iPSC) product platform enables mass production of off-the-shelf, engineered, homogeneous cell products that can be administered with multiple doses to deliver more effective pharmacologic activity, including in combination with cycles of other cancer treatments. Human iPSCs possess the unique dual properties of unlimited self-renewal and differentiation potential into all cell types of the body. The Companys first-of-kind approach involves engineering human iPSCs in a one-time genetic modification event and selecting a single engineered iPSC for maintenance as a clonal master iPSC line. Analogous to master cell lines used to manufacture biopharmaceutical drug products such as monoclonal antibodies, clonal master iPSC lines are a renewable source for manufacturing cell therapy products which are well-defined and uniform in composition, can be mass produced at significant scale in a cost-effective manner, and can be delivered off-the-shelf for patient treatment. As a result, the Companys platform is uniquely capable of overcoming numerous limitations associated with the production of cell therapies using patient- or donor-sourced cells, which is logistically complex and expensive and is subject to batch-to-batch and cell-to-cell variability that can affect clinical safety and efficacy. Fate Therapeutics iPSC product platform is supported by an intellectual property portfolio of over 250 issued patents and 150 pending patent applications.
About FT596
FT596 is an investigational, universal, off-the-shelf natural killer (NK) cell cancer immunotherapy derived from a clonal master induced pluripotent stem cell (iPSC) line engineered with three anti-tumor functional modalities: a proprietary chimeric antigen receptor (CAR) optimized for NK cell biology, which contains a NKG2D transmembrane domain, a 2B4 co-stimulatory domain and a CD3-zeta signaling domain, that targets B-cell antigen CD19; a novel high-affinity 158V, non-cleavable CD16 Fc receptor that has been modified to augment antibody-dependent cellular cytotoxicity by preventing CD16 down-regulation and enhancing CD16 binding to tumor-targeting antibodies; and an IL-15 receptor fusion (IL-15RF) that promotes enhanced NK cell activity. The FDA has allowed investigation of FT596 in an open-label Phase 1 clinical trial as a monotherapy and in combination with rituximab for the treatment of advanced B-cell malignancies and in combination with obinutuzumab for the treatment of chronic lymphocytic leukemia. In preclinical studies of FT596, the Company has demonstrated that dual activation of the CAR19 and CD16 receptors, in combination with IL-15RF signaling, convey synergistic anti-tumor activity. Increased degranulation and cytokine release were observed upon dual receptor activation in lymphoma cancer cells as compared to activation of each receptor alone, indicating that multi-antigen engagement may elicit a deeper and more durable response. Additionally, in a mixed cellular composition cytotoxicity assay comprised of CD19+ and CD19- tumor cells, FT596 combined with CD20-directed monoclonal antibody therapy effectively eliminated the heterogeneous population of tumor cells, a result that was not observed with single-antigen targeted CAR19 T cells.
About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders. The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Companys immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens with chimeric antigen receptors (CARs). The Companys immuno-regulatory product candidates include ProTmune, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit http://www.fatetherapeutics.com.
Forward-Looking Statements
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 including statements regarding the Companys clinical studies and preclinical research and development programs. These and any other forward-looking statements in this release are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that results observed in prior studies of its product candidates, including preclinical studies and clinical trials of any of its product candidates, will not be observed in ongoing or future studies involving these product candidates, and the risk that the Company may cease or delay preclinical or clinical development of any of its product candidates for a variety of reasons (including requirements that may be imposed by regulatory authorities on the initiation or conduct of clinical trials or to support regulatory approval, difficulties or delays in subject enrollment in current and planned clinical trials, difficulties in manufacturing or supplying the Companys product candidates for clinical testing, and any adverse events or other negative results that may be observed during preclinical or clinical development). For a discussion of other risks and uncertainties, and other important factors, any of which could cause the Companys actual results to differ from those contained in the forward-looking statements, see the risks and uncertainties detailed in the Companys periodic filings with the Securities and Exchange Commission, including but not limited to the Companys most recently filed periodic report, and from time to time in the Companys press releases and other investor communications.Fate Therapeutics is providing the information in this release as of this date and does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise.
Contact:
Christina TartagliaStern Investor Relations, Inc.212.362.1200christina@sternir.com
Follow this link:
Fate Therapeutics Announces Six Presentations at the 2019 ASH Annual Meeting - GlobeNewswire
- Organoids: science fiction or the future of pre-clinical studies? - Lexology - October 13th, 2022
- Researchers develop method to study brain connectivity, functionality - Florida Hospital News and Healthcare Report - South Florida Hospital News - October 13th, 2022
- A win for stem cells | Washington Examiner - October 4th, 2022
- TransMedia Group to Illumine Impressive Neuro Healing Results Achieved by Raymond Cralle, a Pioneer in Hyperbaric Oxygen Therapy and a Florida... - September 16th, 2022
- Sure Signs You Have Non-Hodgkin's Lymphoma Eat This Not That - Eat This, Not That - August 22nd, 2022
- New treatment changing outlook for those with blood cancers - WBAL TV Baltimore - July 19th, 2022
- Engineering Graduate Fellows Get Hands-on Experience with National Industry Leaders - UCF - July 11th, 2022
- New Alzheimer's Treatment on Horizon as Dementia Reversed for First Time in Dogs - StreetInsider.com - June 22nd, 2022
- Life Cycle of a Moss - Infographic - STEM Lounge - June 13th, 2022
- Miller School Researchers on the Trail to Unraveling Long COVID-19 - Florida Hospital News and Healthcare Report - South Florida Hospital News - June 4th, 2022
- American Academy of Stem Cell Physicians is Proud to Add to the Speaker Roster, Dr. Scheffer Tseng, Acclaimed Opthamologist and Founder of Bio-Tissue... - May 15th, 2022
- 'Doctors gave me six months to live in 2016 but I continue to defy every expectation' - Wales Online - May 2nd, 2022
- Revolutionary Oxygen Healing Therapy Now Available in Florida - Digital Journal - March 25th, 2022
- Global Mesenchymal Stem Cells Market Analysis, Opportunities, Trend and Forecast To 2029 Discovery Sports Media - Discovery Sports Media - January 20th, 2022
- EDUCATION SPOTLIGHT: Florida Tech Highlights Work Done During 2021 as We Enter the New Year - SpaceCoastDaily.com - January 5th, 2022
- Roundtable Discussion: Shain Looks at the Role of Transplant Eligibility in Patients With Newly Diagnosed Multiple Myeloma - Targeted Oncology - November 8th, 2021
- ALS and dementia attacked by an RNA-hunting compound that recruits cell's own virus fighter - EurekAlert - October 28th, 2021
- Brainstorm Cell, (BCLI) falls 0.65% in Active Trading on October 25 - Equities.com - October 28th, 2021
- Global Mesenchymal Stem Cells Market Prospects, Upcoming Trends and Competitive Outlook till 2028 | Lonza, Thermo Fisher, Bio-Techne, ATCC,... - October 28th, 2021
- Faster healing of wounds can decrease pain and suffering and save lives - WWNY - October 5th, 2021
- US FDA Approves Kite's Tecartus as the First and Only Car T for Adults With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia | DNA RNA and... - October 5th, 2021
- Times really up! FDA authority to crack down on regenerative medicines upheld as grace period ends - JD Supra - July 21st, 2021
- Animal Stem Cell Therapy Market Size, Industry Analysis, Growth Factors, Trends, and Regional Forecast to 2027 - The Courier - March 11th, 2021
- An 8-year-olds search for bone marrow match in battle with leukemia comes to North Texas - The Dallas Morning News - March 11th, 2021
- Eirion Therapeutics, Inc. Closes $40 Million Series A Investment and Licensing Deal with Shanghai Haohai Biological Technology Ltd. - PRNewswire - March 11th, 2021
- How soon will COVID-19 vaccines return life to normal? - Science Magazine - February 16th, 2021
- Keep it Flowing: Combating COVID-19 Blood Shortages in Cancer Treatment - Curetoday.com - February 16th, 2021
- FL Doctors Make Breakthrough Using Stem Cells to Treat ... - February 2nd, 2021
- This Guy Injected His Dick With Stem Cells to Try to Make ... - February 2nd, 2021
- 10 Best Stem Cell Beauty Products On The Market Today - February 2nd, 2021
- HealthLynked's The Future of Healthcare Summit Brings Healthcare Experts and Technology Innovators from Around the World to Naples, Florida -... - February 2nd, 2021
- SpaceX Cargo Dragon Returning To Earth; First U.S. Commercial Cargo Craft To Return From ISS - Science Times - January 8th, 2021
- Buoyed by study, scientists increasingly hopeful first two COVID-19 vaccines effective against new strains - The Boston Globe - January 8th, 2021
- Flavors added to vaping devices damage the heart, vanilla custard the most toxic of all - Study Finds - December 23rd, 2020
- Flavours added to vaping devices can damage the heart: Study - Sify News - December 12th, 2020
- Jabbed for a good cause: Hundreds already getting COVID-19 shots as part of clinical trial - The West Volusia Beacon - August 29th, 2020
- Hesperos demonstrates innovative Human-on-a-Chip approach to modeling innate immune system response following tissue damage and acute inflammation -... - June 8th, 2020
- Hesperos Human-on-a-Chip System Used to Model Preclinical Stages of Alzheimers Disease and Mild Cognitive Impairment - Yahoo Finance - June 4th, 2020
- Can genetics explain the degrees of misery inflicted by the coronavirus? - Genetic Literacy Project - April 21st, 2020
- Beating cancer by taking the unbeaten path | ASU Now: Access, Excellence, Impact - ASU Now - April 9th, 2020
- Reviewing CRYO-CELL International (OTCMKTS:CCEL) and Harsco (OTCMKTS:HSC) - Redmond Register - March 26th, 2020
- Head to Head Analysis: Harsco (NYSE:HSC) & CRYO-CELL International (NYSE:CCEL) - Redmond Register - March 24th, 2020
- Reviewing Harsco (NYSE:HSC) and CRYO-CELL International (NYSE:CCEL) - Redmond Register - March 12th, 2020
- Data On Enlivex's Allocetra-OTS Immunotherapy for Peritoneal Solid Tumors and for Prevention of GvHD Selected for Presentation at the Transplantation... - February 24th, 2020
- Consistent Outcomes Using Ryoncil as First-Line Treatment or Salvage Therapy in 309 Children With Steroid-Refractory Acute GVHD - BioSpace - February 24th, 2020
- NASA to send equipment to International Space Station to research Improving Shoes, Showers, 3D Printing - Clarksville Online - February 24th, 2020
- Here are all the science projects that SpaceX will deliver to the ISS - Digital Trends - February 24th, 2020
- 34 years with a new heart and counting - MDJOnline.com - February 24th, 2020
- 'Florida cold' and the semi-glamorous world of work trips - CT Insider - February 19th, 2020
- 34 Years with a New Heart and Counting | 90.1 FM WABE - WABE 90.1 FM - February 19th, 2020
- Study shows how a tiny and strange marine animal produces unlimited eggs and sperm over its lifetime - National Institutes of Health - February 16th, 2020
- Research - Florida Stem Cell Research - January 3rd, 2020
- Florida Stem Cell Treatment Center - January 3rd, 2020
- Advances In Treatment Of Soft Tissue Injuries (Video) - South Florida Reporter - January 3rd, 2020
- Explained: What is the water crisis Southwest Florida is battling? - Wink News - December 24th, 2019
- Mum shares heartbreaking photo of toddler sobbing through gruelling cancer treatment - The Sun - December 1st, 2019
- World AIDS Day 2019: Theme, History and Facts about HIV and AIDS - Newsweek - December 1st, 2019
- Tulane team researching ways to end opioid addiction - News from Tulane - November 24th, 2019
- Improve global wellbeing with a degree in public health - Study International News - November 12th, 2019
- Reviewing US Stem Cell (OTCMKTS:USRM) and Auxly Cannabis Group (OTCMKTS:CBWTF) - Riverton Roll - November 12th, 2019
- Bloomington Vet Joins Study For Stem Cell Therapy To Treat Dogs With Arthritis - WGLT News - October 24th, 2019
- Brooks Koepka Withdraws in Korea After Reaggravating Knee Injury - Golf Channel - October 24th, 2019
- Walking in His Shoes - Curetoday.com - October 5th, 2019
- The Real Problem With Beef - The New York Times - October 2nd, 2019
- Stem Cell Treatment Clinic St. Augustine - Florida Stem Cell - March 17th, 2019
- Stem Cell Questions - Florida Stem Cell - FAQs - February 2nd, 2019
- Stem Cell Procedure for Erectile Dysfunction - January 26th, 2019
- Stuart Florida Stem Cells | NovaGenix - January 18th, 2019
- Stem Cell Hair Treatment for Hair Loss | Stem Cell Hair Growth - January 3rd, 2019
- South Florida Stem Cell Center | Melvin M. Propis, M.D. - December 11th, 2018
- Florida Stem Cell Treatments - Regenerative Orthopedic ... - December 11th, 2018
- Florida - Stem Cells Transplant Institute - July 24th, 2018
- FDA: Florida Stem Cell Clinic Violates Law | Health News ... - October 18th, 2017
- Stem cell research | UF Health, University of Florida Health - October 18th, 2017
- FDA: Serious Problems at Florida Stem Cell Clinic - WebMD - August 29th, 2017
- FDA Cracks Down On Stem-Cell Clinics Selling Unapproved Treatments - KRCB - August 29th, 2017
- US FDA steps up scrutiny of stem cell therapies - Reuters - August 29th, 2017
- Paralyzed After Pool Accident, Student Heads Back To College - News Talk Florida - August 29th, 2017
- SpaceX to Launch NASA Cargo, Try Rocket Landing Today: Watch It Live - Space.com - August 16th, 2017
- Dragon Splashes Down to Complete Resupply Mission - Space Daily - July 7th, 2017